Investigating how RGS12 affects pain relief and side effects from kappa opioid receptor activation
The role of RGS12 in differential modulation of G protein versus beta-arrestin signaling downstream of the kappa opioid receptor
This study is looking at how a specific protein affects the way certain medications that target stress and pain work, with the goal of making these medications more helpful and less likely to cause unwanted side effects for people dealing with chronic pain, addiction, anxiety, or depression.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of North Texas Hlth Sci Ctr NIH-funded |
| Lab location | 1 site (Fort Worth, United States) |
| Project ID | NIH-10997411 on NIH RePORTER |
What this research studies
This research focuses on the kappa opioid receptor (KOR), which plays a role in stress responses and is linked to chronic pain, addiction, anxiety, and depression. The study aims to understand how RGS12, a protein that regulates signaling pathways, influences the beneficial effects of KOR agonists, such as pain relief, while also contributing to negative side effects like dysphoria. By examining the mechanisms of G protein and beta-arrestin signaling, the research seeks to identify ways to enhance the therapeutic effects of KOR agonists while minimizing their adverse effects.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals experiencing chronic pain, addiction, anxiety, or depression who may benefit from new analgesic treatments.
Not a fit: Patients who do not have chronic pain or related disorders may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved pain management therapies with fewer side effects for patients suffering from chronic pain and related disorders.
How similar studies have performed: Previous research has shown promise in targeting KOR signaling pathways, suggesting that this approach may lead to significant advancements in treatment options.
Where this research is happening
Fort Worth, United States
- University of North Texas Hlth Sci Ctr — Fort Worth, United States (Active)
Researchers
- Principal investigator: Siderovski, David P. — University of North Texas Hlth Sci Ctr
- Study coordinator: Siderovski, David P.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.